ABBV News and Press, AbbVie Inc. From 02/19/26

2026-02-19 09:39:32 ET More on AbbVie AbbVie: Dominating Immunology While Building Oncology Upside AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript AbbVie: The Market Is Getting It Wrong AbbVie files lawsui...

2026-02-18 22:38:10 ET Since my last article in August, "Incyte: Wall Street Underestimates Strength of Ruxolitinib Portfolio," Incyte shares ( INCY ) are up 19.1%.... Read the full article on Seeking Alpha For further details see: Incyte Remains Undervalued As O...

2026-02-18 21:15:00 ET The following segment was excerpted from the Harbor Dividend Growth Leaders ETF Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Harbor Dividend Growth Leaders ETF Q4 Contributors ...

2026-02-18 14:13:52 ET More on Pfizer, Johnson & Johnson, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction ...

2026-02-18 10:57:00 ET Regardless of whether you are looking at a growth stock or dividend stock, cash flow is key. However, when analyzing the safety and reliability of a dividend, cash flow is a must. In today's video, I am going to breakdown 6 companies that all have solid free cash ...

2026-02-17 01:11:27 ET AbbVie ( ABBV ), a leader in the JAK and IL-23 inhibitor markets, released strong Q4 numbers, but its stock price fell 5.1% that day. And first, I will note the dry numbers.... Read the full article on Seeking Alpha For further details see: AbbVie:...

2026-02-16 09:45:00 ET When it comes to 2026, we have seen the rotation out of technology, but that excites me more than it concerns me, as I get an opportunity to buy high quality names at great valuaitons. In today's video, I am going to look at 8 stocks that have had bumpy rides, but...

2026-02-15 17:25:00 ET Despite its fourth-quarter results being pretty solid, the share price of pharmaceutical giant AbbVie (NYSE: ABBV) fell after the company released earnings last week. The market reacted poorly to details in the drugmaker's earnings report, but the long-term ou...

2026-02-15 09:16:00 ET All 5 stocks that I will discuss in today's video have gone through some sort of pullback, and that volatility is expected to continue throughout the foreseeable future as investors rotate. However, some it appears like the sell-off has been overdone and I want these ...

2026-02-14 08:35:00 ET A survey last fall by Natixis Investment Managers found that 74% of institutional money managers expect a market correction in 2026. They cited various reasons, from the tech bubble bursting to geopolitics and macroeconomic factors. Currently, the Nasdaq Composite ...